Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

FDA approves new short-term treatment for AFib, atrial flutter in critical care settings
Landiolol, sold by AOP Health under the brand name Rapiblyk, is an intravenous treatment designed to start working right away.
FDA approves acoramidis, BridgeBio’s new ATTR-CM drug
Acoramidis, a selective transthyretin stabilizer being sold under the brand name Attruby, is now the second ATTR-CM medication to gain FDA approval.
Medtronic receives key FDA clearance, launches new diabetes system
Medtronic designed its new Smart MDI system to provide real-time insights to users on multiple daily injection therapy.
ATTR-CM drug acoramidis, now approved by the FDA, linked to positive long-term data
Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.
Martha Gulati highlights 'exciting' progress in preventive cardiology
Martha Gulati, MD, spoke to Cardiovascular Business at AHA Scientific Sessions 2024 about key developments in obesity treatment and CVD prevention.

USPSTF shares updated recommendations on statin use to prevent CVD

The public comment period for these recommendations ends on March 21.

February 22, 2022

Ticagrelor alone after DAPT lowers bleeding risk among heart attack patients undergoing PCI

Researchers examined data from the TWILIGHT study to track how different treatment strategies can impact 12-month PCI outcomes.

February 16, 2022

LAAC or DOACs? How treatment strategies for AFib impact long-term outcomes

The new analysis provided an update on data from the PRAGUE-17 trial.

January 11, 2022

DOACs underprescribed among high-risk AFib patients

The study found that frail patients with AFib are less likely to be treated with DOAC therapy.

December 20, 2021

Metoprolol demonstrates value as a treatment for obstructive hypertrophic cardiomyopathy

The small study, published in the Journal of the American College of Cardiology, compared patient outcomes associated with metoprolol and a placebo.

December 20, 2021

DOACs outperform VKAs among cardiac amyloidosis patients with HF, AFib

Outcomes from patients prescribed apixaban, rivaroxaban or dabigatran were compared with outcomes from patients given warfarin.

December 2, 2021

Generic statin options can save the US $11.9B per year

The study tracked five generic statins: atorvastatin, rosuvastatin, simvastatin, lovastatin and pravastatin.

November 23, 2021

Q&A: Cleveland Clinic cardiologist details the past, present and future of drug-eluting stents

Amar Krishnaswamy, MD, shared his thoughts on this important technology in an exclusive interview.

November 22, 2021

Around the web

Health Imaging

Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Pharmaceutics

FDA approves new short-term treatment for AFib, atrial flutter in critical care settings

FDA approves acoramidis, BridgeBio’s new ATTR-CM drug

Medtronic receives key FDA clearance, launches new diabetes system

ATTR-CM drug acoramidis, now approved by the FDA, linked to positive long-term data

Martha Gulati highlights 'exciting' progress in preventive cardiology

Around the web